Investigating Chelating Sulfonamides and Their Use in Metalloproteinase Inhibitors

Overview

Journal Dalton Trans

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2012 Mar 14

PMID 22411188

Citations 8

Authors

Alisa Tanakit

Matthieu Rouffet

David P Martin

Seth M Cohen

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinase inhibitors (MMPi) utilize zinc-binding groups (ZBGs) to chelate the catalytic Zn(II) ion resulting in enzyme inhibition. Adapting findings from the literature of Zn(II) ion sensors, we previously reported chelating sulfonamide inhibitors of MMP-2, some of which showed excellent selectivity over other gelatinases (MMP-9). Herein, we greatly expand our investigation of chelating sulfonamides as MMP inhibitors (MMPi) with the synthesis and screening of several new libraries consisting of 2-phenyl-7-sulfonamidobenzimidazole, 2-phenyl-7-sulfonamidobenzoxazole, 7-sulfonamidobenzimidazole, 7-sulfonamidobenzoxazole, and 2-(2-sulfonamidophenyl)-quinoline ZBG derivatives. A novel microwave irradiation synthetic procedure was utilized to rapidly and efficiently prepare these molecules. To better understand the coordination chemistry underlying these ZBGs, crystal structures of representative molecules with several first row transition metals were determined and differences in coordination preferences were considered. Surprisingly, only compounds with the 2-phenyl-7-sulfonamidobenzimidazole ZBG showed inhibition of MMP-2, suggesting that the specific structure of the ZBG can have a pronounced effect of inhibitory activity.

Citing Articles

Decoding the Implications of Zinc in the Development and Therapy of Leukemia.

Zhu B, Yang C, Hua S, Li K, Shang P, Li Z Adv Sci (Weinh). 2025; 12(9):e2412225.

PMID: 39887881 PMC: 11884550. DOI: 10.1002/advs.202412225.

Discovery of a Potent and Highly Selective Dipeptidyl Peptidase IV and Carbonic Anhydrase Inhibitor as "Antidiabesity" Agents Based on Repurposing and Morphing of WB-4101.

Artasensi A, Angeli A, Lammi C, Bollati C, Gervasoni S, Baron G J Med Chem. 2022; 65(20):13946-13966.

PMID: 36201615 PMC: 9937538. DOI: 10.1021/acs.jmedchem.2c01192.

Developing Metal-Binding Isosteres of 8-Hydroxyquinoline as Metalloenzyme Inhibitor Scaffolds.

Seo H, Jackl M, Kalaj M, Cohen S Inorg Chem. 2022; 61(19):7631-7641.

PMID: 35507007 PMC: 9912809. DOI: 10.1021/acs.inorgchem.2c00891.

Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.

Baggio C, Velazquez J, Fragai M, Nordgren T, Pellecchia M J Med Chem. 2020; 63(21):12911-12920.

PMID: 33107733 PMC: 8544245. DOI: 10.1021/acs.jmedchem.0c01285.

Recent insights into natural product inhibitors of matrix metalloproteinases.

Kumar G, Nair B, Perry J, Martin D Medchemcomm. 2020; 10(12):2024-2037.

PMID: 32904148 PMC: 7451072. DOI: 10.1039/c9md00165d.

References

Jacobsen F, Lewis J, Cohen S . The design of inhibitors for medicinally relevant metalloproteins. ChemMedChem. 2006; 2(2):152-71. DOI: 10.1002/cmdc.200600204. View

Jacobsen F, Cohen S . Using model complexes to augment and advance metalloproteinase inhibitor design. Inorg Chem. 2004; 43(10):3038-47. DOI: 10.1021/ic035388o. View

Puerta D, Cohen S . Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes. Inorg Chem. 2002; 41(20):5075-82. DOI: 10.1021/ic0204272. View

Coussens L, Fingleton B, Matrisian L . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. DOI: 10.1126/science.1067100. View

Yiotakis A, Dive V . Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. Mol Aspects Med. 2008; 29(5):329-38. DOI: 10.1016/j.mam.2008.06.001. View

Rao B . Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des. 2005; 11(3):295-322. DOI: 10.2174/1381612053382115. View

Beckman J, Kincaid K, Hocek M, Spratt T, Engels J, Cosstick R . Human DNA polymerase alpha uses a combination of positive and negative selectivity to polymerize purine dNTPs with high fidelity. Biochemistry. 2007; 46(2):448-60. PMC: 2515318. DOI: 10.1021/bi061243s. View

Puerta D, Cohen S . Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg Chem. 2003; 42(11):3423-30. DOI: 10.1021/ic026029g. View

McRae R, Bagchi P, Sumalekshmy S, Fahrni C . In situ imaging of metals in cells and tissues. Chem Rev. 2009; 109(10):4780-827. PMC: 3812694. DOI: 10.1021/cr900223a. View

10.

Henary M, Wu Y, Cody J, Sumalekshmy S, Li J, Mandal S . Excited-state intramolecular proton transfer in 2-(2'-arylsulfonamidophenyl)benzimidazole derivatives: the effect of donor and acceptor substituents. J Org Chem. 2007; 72(13):4784-97. DOI: 10.1021/jo070433l. View

11.

Lindsey M . MMP induction and inhibition in myocardial infarction. Heart Fail Rev. 2004; 9(1):7-19. DOI: 10.1023/B:HREV.0000011390.44039.b7. View

12.

Whittaker M, Floyd C, Brown P, Gearing A . Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 2001; 99(9):2735-76. DOI: 10.1021/cr9804543. View

13.

Hendrickson K, Geue J, Wyness O, Lincoln S, Ward A . Coordination and fluorescence of the intracellular Zn2+ probe [2-methyl-8-(4-toluenesulfonamido)-6-quinolyloxy]acetic acid (Zinquin A) in ternary Zn2+ complexes. J Am Chem Soc. 2003; 125(13):3889-95. DOI: 10.1021/ja020685y. View

14.

Puerta D, Lewis J, Cohen S . New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J Am Chem Soc. 2004; 126(27):8388-9. DOI: 10.1021/ja0485513. View

15.

Martin D, Rouffet M, Cohen S . Illuminating metal-ion sensors: benzimidazolesulfonamide metal complexes. Inorg Chem. 2010; 49(22):10226-8. PMC: 2975806. DOI: 10.1021/ic101700t. View

16.

Henary M, Wu Y, Fahrni C . Zinc(II)-selective ratiometric fluorescent sensors based on inhibition of excited-state intramolecular proton transfer. Chemistry. 2004; 10(12):3015-25. DOI: 10.1002/chem.200305299. View

17.

Nuti E, Tuccinardi T, Rossello A . Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des. 2007; 13(20):2087-100. DOI: 10.2174/138161207781039706. View

18.

Puerta D, Mongan J, Tran B, McCammon J, Cohen S . Potent, selective pyrone-based inhibitors of stromelysin-1. J Am Chem Soc. 2005; 127(41):14148-9. DOI: 10.1021/ja054558o. View

19.

Puerta D, Griffin M, Lewis J, Romero-Perez D, Garcia R, Villarreal F . Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem. 2006; 11(2):131-8. DOI: 10.1007/s00775-005-0053-x. View

20.

Pirard B . Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today. 2007; 12(15-16):640-6. DOI: 10.1016/j.drudis.2007.06.003. View